在改善脂质配置参数方面,Inclisiran与alirocumab对比:系统性审查和元分析
André Saad Cleto1, João Matheus Schirlo1, Victor Hugo Oliveira Gomes1
1Department of Medicine, State University of Ponta Grossa, Paraná, Brazil.
阿利罗库马布在改善脂质配置文件方面表现出比因克利西兰更高的疗效,显著降低了LDL-C,总胆固醇和甘油三. 这一发现对患有抗常规治疗的脂质失调症患者至关重要.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 脱脂症对心血管疾病构成重大风险.
- 传统治疗对一些患者无效,需要替代疗法.
- PCSK9抑制剂为耐火性脂质失调症提供了潜在的治疗途径.
结论:
- 阿利罗马布在改善脂质谱方面比英克利西兰更有效.
- 阿利罗库马布在降低低密度脂蛋白胆固醇 (LDL-C),总胆固醇和甘油三醇方面表现出卓越的疗效.
- 这些发现支持阿利罗库马布作为一种潜在的更有效的PCSK9抑制剂来控制脂质不良症.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Assembly of the Lipid Bilayer in the ER
A large chunk of any biological membrane is composed of phospholipids. These lipids have a heterogeneous distribution across different subcellular organelles and even between...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Dipeptidyl Peptidase 4 Inhibitors
